11 countries
import products manufactured by the company
At the beginning of the year NPO Petrovax Pharm invested over 900 million rubles in a new production line that meets all GMP requirements, allowing a two-and-a-half-fold increase in the production of pharmaceutical substances, a seven-fold increase in the production of pills, and a quadrupling of its suppositories production capacity.
In March, NPO Petrovax Pharm was again certified by the Ministry of Industry and Trade as having a manufacturing and management systems compliant with the GMP quality requirements, thus confirming that the company meets their high standards. Soon after, Petrovax Pharm announced an extension of the recommended age group for the use of Polyoxidonium ® to include children starting at 3 years old.
In June, under the sponsorship of NPO Petrovax Pharm and the Interros Group, the country-wide scientific forum «Days of Immunology in Saint Petersburg» held its sixteenth session in Saint-Petersburg.
In July, the company received a report on the successful conclusion of the EU post-authorization safety study (PASS) for Polyoxidonium ® in injections. The study confirmed its high tolerability and safety profile in patients.
In August, NPO Petrovax Pharm began exporting more than 2 million doses of the Grippol Plus ® flu vaccine to Kazakhstan. In October, a wide-spread free immunization campaign began in Belarus, for which the government procured Grippol Plus ® vaccine from NPO Petrovax Pharm.
In the middle of October the first batches of Metalize ®, a drug to treat acute myocardial infarction, became available to patients in Russia. Production was localized in Russia in partnership with Boehringer Ingelheim. At the end of the month, Petrovax Pharm received an ISO 9001:2015 management quality control system compliance certificate. In addition to the main ISO 9001:2015 certificate, Petrovax also obtained an IQNet single international certificate.
At the end of the year, the company donated 200 thousand doses of Grippol Plus® vaccine to clinics in the Moscow region to prevent flu epidemic.
Polyoxidonium ® won Russian Pharma Awards 2017, an annual competition held for the 6th time, in the «Drug of Choice to Prevent and Treat Acute Respiratory Infection and Flu in Children» category.